High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

Table 5 Six-min walk test. Secondary endpoint

Group	W0	W12	W24	W36	W48	Absolute change between W0 and W48	p-value
CIDP	240 (225;300)	268 (238;332)	293 (265;384)	253 (248;360)	248 (226;392)	91 (8;92)
anti-MAG	435 (375;479)	467 (390;540)	479 (444;489)	432 (422;536)	489 (444;494)	59 (10;69)
CMT1	439 (375;474)	469 (442;479)	474 (432;511)	478 (434;513)	479 (469;556)	82 (40;104)
All patients	375 (293;474)	419 (315;470)	442 (293;489)	427 (285;489)	469 (278;506)	69 (10;104)	< .001

Missing data at W48 were imputed with the LOCF method (W36 for patient #04, CIDP group). The results were considered regardless of walking assistance. The results are expressed in meters as median (IQR) in CIDP group (n = 5), anti-MAG group (n = 5), CMT1 group (n = 5) and in all patients (n = 15). The P-value was calculated with the Wilcoxon signed rank test in all patients (n = 15)

ISSN: 1471-2377